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Mycobacterium tuberculosis is the causative agent of tuberculosis disease, which has developed a myriad of exceptional features
contributing to its survival within the hostile environment of host cell. Unique cell wall structure with high lipid content plays
an imperative role in the pathogenicity of mycobacteria. Cell wall components of MTB such as lipoarabinomannan and Trehalose
dimycolate (cord factor) are virulent in nature apart from its virulence genes. Virulent eﬀect of these factors on host cells reduces
host cell immunity. LAM has been known to inhibit phagosome maturation by inhibiting the Ca2+/calmodulin phosphatidyl
inositol-3-kinase hvps34 pathways. Moreover, TDM (Trehalose dimycolate) also inhibits fusion between phospholipid vesicles and
migration of polymorphonuclear neutrophils. The objective of this paper is to understand the virulence of LAM and cord factor
on host cell which might be helpful to design an eﬀective drug against tuberculosis.
1.Introduction
Mycobacteriumtuberculosis(MTB)isexceptionallysuccessful
pathogen with unique characteristic features which make it
highly pathogenic [1]. Cell wall of MTB is composed of 60%
of lipids. Major fraction of its cell wall is mycolic acid, Cord
factor, and Wax-D [2, 3]. The cell wall of MTB is composed
of two segments: outer part and core of cell wall (Figure 1).
Core of cell wall is made up of peptidoglycan (PG),
covalently attached with arabinogalactan (AG) and mycolic
acids subsequently, forming the mycolyl arabinogalactan-
peptidoglycan (mAGP) complex. Upper part is composed
of free lipids which are linked with fatty acids. Mostly this
part is made up of diﬀerent cell wall proteins, the phos-
phatidylinositol mannosides (PIMs), Lipomannan (LM),
and Lipoarabinomannan (LAM). These proteins along with
lipids and glycoconjugate lipids act as eﬀector molecules of
signaling process, and the insoluble core is essential for the
viability of the cell [3]. LAM blocks phagosomal maturation
in host cell either by blocking the traﬃcking pathway from
trans-Golgi network (TGN) to phagosomes which itself
depends on early endosomal autoantigen 1 (EEA1), an
essential Rab5 factor recruitment to early phagosomes, or by
inhibiting the Ca2+ concentration in macrophages, as Ca2+ is
an essential factor for phagosomal maturation [4]. Another
virulence factor, produced by MTB, is Cord factor. Cord
factor behaves diﬀerentially according to its localization.
It is nontoxic, when present on organisms and protects
t h e mf r o mm a c r o p h a g ed e s t r u c t i o n ,b u ti tb e c o m e st o x i c
on lipid surfaces. TDM inhibits the phagosome-lysosome
fusion and contributes to the maintenance of granulomatous
response. Removal of surface lipids enhances traﬃcking
of organisms to acidic compartments [5]. Accumulation
of TDM causes weight loss in organisms, resulting in the
condition known as Cachexia. In this condition, animals
exhibit hypertriglyceridemia, hypoglycemia, and Tumor-
Necrosisfactor(TNF)inplasma[6].MTBproducesdiversity
of lipids which are responsible for its pathogenicity.
2. Lipoarabinomannan(LAM)
Lipoarabinomannan commonly known as LAM, is a glyco-
conjugate and one of the virulence factor associated with
MTB. It is a major cell wall component and allows the
MTB to survive in host cell environment by aﬀecting host
resistance and immune responses [7]. LAM inhibits T-
cell proliferation and bactericidal activities of macrophages2 Biotechnology Research International
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Figure 1: Structure of mycobacterial cell wall.
[8]. In addition, LAM eliminates cytotoxic oxygen-free
radicals produced by macrophages and inhibits the activity
of protein kinase C and also blocks the activation of gamma-
interferon at transcriptional level [8]. LAM is capped with
short mannose containing oligosaccharides which allow the
bacteria to bind with the mannose receptors present on
the macrophages. LAM also has ability to bind with the
toll receptors and thus can insert itself into biological
membranes aﬀecting signaling events [3]. LAM causes the
release of TNF in vitro in human blood monocytes and
in vivo in mice. TNF release may be responsible for the
characteristics of tuberculosis, such as, loss in weight, fever,
andcytokine-mediatednecrosis[9].Itwasalsoobservedthat
LAM binds to the DC-SIGN molecule which is expressed on
the surface of dendritic cells.
DC-SIGN is indispensable for the maturation of den-
dritic cells, but binding of LAM inhibits the process. This
inhibition also results in decreased IL-12 production and
induction of dendritic cells to secrete IL-10, which in turn
inhibits antigen presentation, expression of MHC molecules,
and costimulatory receptors. In view of these observations
recent studies also found that TB patients exhibit consider-
ably elevated levels of IL-10 [10]. This can be demonstrated
in vitro by the inhibition of polyethylene glycol- (PEG-)
induced lipid vesicle fusion with Fluorescence resonance
energy transfer (FRET). PEG absorbs water molecules
around the lipid vesicles and promotes fusion of these
vesicles. Lower FRET signals are obtained with LAM, which
shows that LAM inhibits the association of adjacent vesicles.
Instead of Polyethylene glycol (PEG), SNARE proteins act as
fusion attachment receptors in vivo [11].
LAM is virulent in nature and causes phagosome mat-
uration arrest by blocking Ca2+/Calmodulin phosphatidyl–
inositol-3-kinase hvps34 pathways resulting in the long-term
survival of MTB in host cell environment [12].
2.1. Structure. LAM is mainly made-up of three com-
ponents: membrane anchor, mannosyl-phosphatidyl-myo-
inositol, backbone, mannopyranose, and arabinofuranose
which are homopolysaccharides and the capping motif.
Membrane anchor attaches the molecule to cell wall at
the time of infection, and homopolysaccharides serve as
carbohydrate skeleton [13, 14].
2.2. Classiﬁcation of LAM. Classiﬁcation of LAM is based on
the presence and structure of capping and classiﬁed LAMs
into three major classes.
2.2.1. Mannosylated LAMs (Man LAM). In Man LAMs,
mannosyl groups are present on the D-arabinan group. After
the mannosyl capping, Man LAM acts as anti-inﬂammatory
molecule and inhibits the production of TNF-α and IL-
1 2 .T h e s ep r o p e r t i e so fM a nL A Ma l l o wt h eb a c t e r i at o
survive in the host cell for long time. Man LAMs are mainly
found in pathogenic mycobacterial species such as MTB,
Mycobacterium leprae (M. leprae), and Mycobacterium bovis
(M. bovis)[ 15].
2.2.2. Phosphoinositol-Capped LAM (PILAM). LAMs capped
with phosphoinositol groups are called as PILAMs, mainly
found in nonpathogenic species such as Mycobacterium
smegmatis (M. smegmatis). PILAMs can bind with CD14
receptor, present on macrophages. CD14 receptor is associ-
ated with toll like receptor 2 (TLR 2) which acts as recogni-
tion receptor for PILAMs. PILAMs induce the production of
cytokines such as TNF-alpha, IL-8, and IL-12 [16].
2.2.3. Arabinofuranosyl-Terminated LAM (Ara LAM). Ara
LAM 1, 3-mannosyl side chains are present instead of 1, 2-
mannosyl side chain, commonly found in many mycobacte-
rial species. Ara LAM also induces the production of many
cytokines such as TNF-alpha, IL 1-alpha, IL 1-β,I L - 6 ,I L -
8, and IL-10. Ara LAM is generally found in Mycobacterium
chelonae(M.chelonae)andlaboratorystrains,M.tuberculosis
H37Ra [15].
2.3. Biosynthesis of LAM. Many other lipid components of
bacterial cell wall like LM and PIMs are involved in the
synthesis of LAM. LAM is synthesized by the addition of
mannopyranosyl to a phosphoinositol. PIMs are considered
as precursors of LAMs in the biosynthesis pathway [9]. PIMs
and LM are synthesized by the addition of mannopyranosylBiotechnology Research International 3
to a phosphoinositol. Glycosylation of PIMs and LM with
arabinan forms LAM. Mannosyltransferases are involved in
the synthesis of PIMs encoded by the diﬀerent genes as
shown in Table 1. PIMs have been recognized as the major
nonpeptidic Antigens of the host immune responses. PIMs
arealsoTLR-2agonistsandareinvolvedinthestimulationof
unconventional αβ T lymphocytes in the perspective of CD-
1 proteins. PIMs contribute in the opsonic and nonopsonic
bindingofMTBtophagocyticandnonphagocyticcells,since
it is recognized by the C-type lectins, mannose receptor
(MR), mannose binding protein (MBP), and DC-SIGN.
Degree of mannosylation of PIMs and their fatty acyl
appendages are crucial to their interactions with host cells
[17].
Mannosyl transferase, Pim A transfers one ManP group
to the 2-position of the myo-inositol of PI, which is now
converted in PIM1. Pim B transfers one ManP group to the
6 position of the myoinositol of PIM1 to form PIM2. PimA
and Pim B both use GDP-Mannose as the sugar donor. Pim
C transfers another group of ManP to PIM2 to form PIM3,
using GDP-mannose as the sugar donor. Higher PIMs are
formed by the further mannosylation of PIM3 with diﬀerent
mannosyl transferases. These PIMs are precursors for the
synthesis of LM and LAM as shown in Figure 2.L Mi s
glycosylated with arabinan to form LAM [18].
PimF is involved in the synthesis of higher PIMs and
involved in a later step of PIM synthesis. PimF transfers
two sequential mannose group to AC4PIM5, resulting in the
synthesis of AC4PIM7, an intermediate in the biosynthetic
pathway of LAM. Mutation in PimF gene causes accumu-
lation of AC4PIM5 but the synthesis of Pim6 species is
not aﬀected. Acylation of Pim1 and Pim2 is mediated by
Rv2611c, an acyltransferase [20].
2.4. Maturation of Phagosomes into Phagolysosomes. Phago-
somal maturation is a biological process in which phago-
somes interact with endosomes and lysosomes. The mem-
braneremovedatthetimeofmaturationofphagosomesinto
phagolysosomes. Maturing phagosomes form phagolyso-
somes which are essential for the destruction of foreign
particles. Late endosomal and lysosomal constituents deliv-
ered to phagosomes via various sorting pathways [21, 22].
Two speciﬁc rab5 factors are essential for the maturation
of phagosomes; (a) the phosphatidyl-inositol (PI) 3 kinase
hvps34 and (b) early endosome autoantigen (EEA) [23],
which interacts with endosome via its phosphatidyl-inositol-
3-phosphate binding domain. These rabs are active when
present in GTP-bound state and inactive when present in
GDP-bound state. Replacement of rab5 by rab7 is essential
for the maturation of phagosomes. The contents of early
stage of phagosomes delivered to the late phagosomes via
vesicular and intracellular membrane traﬃcking [24]. EEA1
binds with phagosomes by interacting with PI3P which
is generated on early stage of phagosomes by the rab5
eﬀector hvps34 [25]. Additional elements such as Rabaptin-
5[ 26], tuberin (a Rab5-GTPase activating protein) [27],
Rabex 5 (a Rab 5 nucleotide exchange factor) [28] also
participate in membrane tethering and fusion. EEA1 causes
membrane fusion via interacting with the SNARE syntaxin
13, SNARE priming factor NSF, and alpha-SNAP, essential
for the membrane-tethering and fusion [29].
2.5. LAM Causes Phagosome Maturation Arrest. LAM
contributes to MTB’s pathogenicity by blocking the
phosphatidyl-inositol-3-kinase- and phosphatidylinositol-
3-phosphate-dependent pathways, resulting in blocking of
phagosome maturation [30]. LAM inhibits the recruitment
of EEA1 to the early phagosome which is an essential factor
for the maturation of phagosomes. LAM also inhibits Ca2+
increase which is required for the Ca2+/Calmodulin-PI3K
hvps34pathways,essentialforthePI3Pproduction.PI3Pacts
asa mediator forthe association ofphagosome andlysosome
via EEA1 rab5 factor. An increase in the concentration of
Ca2+ prolongs the binding of Ca2+/Calmodulin to CAMK
II, a Serine/Threonine Kinase essential for the EEA1
recruitment to phagosome [5].
Apart from this, a coat protein, TACO, also inhibits
the delivery of phagosomal contents to lysosomes, thus
prevents the lysosomal delivery of mycobacteria and allow
mycobacteria to survive in host macrophages for long time.
TACOisformedaroundthephagosomesafterinfection[31].
3. Cord Factor (Trehalose 6,
6-di-mycolate;TDM)
Cord factor is the most abundant glycolipid in the mycobac-
terial cell wall [32], one of the major constituent of MTB
cell wall, is toxic to mammalian cells, and aﬀects the host
immune system by inhibiting the migration of polymor-
phonuclear neutrophils [33]. Cord factor has long chain
lipids as structural component of the hydrophobic cell wall
which is found to be crucial for the survival of mycobacteria
within phagosomes of host [34]. Cord factor is responsible
for the speciﬁc microscopic morphology called serpentine
cords [35].
3.1. Structure. Cord factor molecules are made up of tre-
halose sugar which is esteriﬁed to two mycolic acid residues.
Length of the residues can vary from species to species but
generally these are present in the range of 20–80 carbons
[36].Twomoleculesofmycolicacidsandonemoleculeofthe
disaccharide trehalose are obtained from alkaline hydrolysis
of cord factor [37].
3.2. TDM Inhibits Fusion between Phospholipid Vesicles: Like
PhagosomesandLysosomes. TDMconsistsoftrehalosewhich
is attached to hydrophobic components. So, TDM inhibits
fusion between two phospholipids bilayers by immobilizing
the trehalose at the aqueous interphase. It acts as a barrier
to fusion by increasing hydration force and creating a
steric hindrance to fusion [38–41]. It has been proved that
intact cord factor is required for the inhibition of fusion of
phospholipid vesicles, as the free mycolic acid molecules and
free trehalose are not able to inhibit fusion of vesicles [36].
In addition, cord factor also stimulates NADase activity
in host cell, thus lowering the level of NAD, especially in
liver, lung, and spleen. As a result, it reduces the activity of4 Biotechnology Research International
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Figure 2: Biosynthesis of LAM in mycobacteria. PI: Phosphatidyl-myo-inositol, PIM: Phosphatidylinositol mannoside, AC2PIM2:
diacylphosphatidylinositol dimannoside, AC2PIM3: diacylphosphatidylinositol trimannoside, AC3PIM2: triacylphosphatidylinositol
dimannosides, AC3PIM3: triacylphosphatidylinositol trimannoside, AC4PIM2: tetra-acylated Phosphatidyl-myo-inositol dimannoside,
AC4PIM3: tetra-acylated Phosphatidyl-myo-inositol trimannoside, PIM4: Phosphatidylinositol tetramannoside, PIM5: Phosphatidylinos-
itol pentamannoside, PIM6: Phosphatidylinositol hexamannoside, PIM7: Phosphatidylinositol heptamannoside, LM: lipomannan, LAM:
Lipoarabinomannan.
Table 1: Diﬀerent genes involved in the biosynthesis of LAM.
Name of gene Function Family Group References
Pim A Conversion of PI into PIM1
(According to the classiﬁcation
of glycosyltransferases) 4
(According to the
Pfam data base) 1 Pim B Conversion of PIM1 into PIM2 [19]
Pim C Conversion of PIM2 into PIM3
Pim F Conversion of AC4PIM5 into
AC4PIM7 22 [ 20]
NAD-dependent enzymes. Oxidative phosphorylation and
electron transport chain in mitochondria are also aﬀected
by the cord factor-mediated disruption of mitochondrial
membranes [42].
3.3. Unique Biological Behavior of Cord Factor. Biological
activities of Cord factor are dependent on its physical
conformation. Cord factor is amphiphilic by nature and
it forms micelles in aqueous medium and monolayer on
hydrophobic surfaces. In monolayer formation, trehalose
and mycolate domains are arranged in two dimensions and
form crystal structure [43–45]. The outer surface of micelle
is completely made-up of trehalose molecules which make
it hydrophilic, and mycolate groups are covered in inner
part of micelle [46]. Both micellar and monolayer forms
have diﬀerent biological properties. In micellar form, TDM
is nontoxic but in monolayer conﬁguration, it becomes
highly toxic. As soon as macrophages come in contact
with them, they are killed by mycobacterium [47]. TDM
also acquire distinctive immunostimulatory activity, such
as humoral responses, granulomagenesis, adjuvant activity
for cell-mediated immune responses, and tumor regression
[32].
3.4. Host Immune System versus TDM. TDM induces host
immune system to secrete cytokines as immune response.
Initially macrophages are present in their resting stage. After
phagocytosis of bacilli, they gain activity. CD4 and CD8
T-cells are responsible for the immune response of host cells
against MTB infection. Macrophages act as antigen present-
ing cells and interact with CD4 T-cells. CD4 T-cells release
IFN-γ after this interaction, which stimulates macrophages
for the release of cytokines such as TNF-α,I L - 1 ,I L- 1 β,I L -
12, and IL-6. Host macrophages produce higher amount of
proinﬂammatory cytokines, when exposed to TDM. These
cytokines are essential for the formation of granulomas. ItBiotechnology Research International 5
Table 2: Role of TDM in diﬀerent forms of TB.
Type of
tuberculosis Role of TDM References
Primary
tuberculosis
(1) For survival of MTB in host
cell environment mainly in
macrophages by inhibiting
phagosome-lysosome fusion.
[50]
(2) At the time of caseating
granulomas formation, a
suﬃcient dose of TDM is
required.
[5]
Secondary
tuberculosis
(1) Preliminary stage of
secondary tuberculosis is called
as lipid pneumonia, which is
caused by the infected material
spilled from granuloma cavities.
[51]
(2) Due to the presence of TDM,
MTB is able to survive in foamy
alveolar macrophages.
(3) Bronchial obstruction takes
place either because of
granuloma or lipid content
present on MTB cell wall.
[52–54]
Caseation
necrosis
(1) TDM monolayer triggers
caseation necrosis in MTB. [55]
(2) Toxic eﬀects of TDM
contribute to the maintenance of
the lesions.
also induces chemokine production like as MCP-1 and MIP-
1α [48]. In a study it was also proposed that TDM can also be
converted into glucose mono mycolate (GMM) inside host
cell [49]. In a biochemical study, it has been postulated that
TDM is a direct Mincle ligand. Based on this observation,
a study was carried out to show that mycobacteria causes
conversion of TDM into GMM upon infection into host
in order to escape from Mincle- mediated host immunity
[50].
3.5. Viability of MTB in Host Macrophages. Petroleum ether
methods are used to remove TDM from virulent M. tubercu-
losis and MTB becomes delipidated [34]. Delipidated MTB is
lessviablethannativeMTB.SurvivalofMTBinmacrophages
is reduced after delipidation. Cells which are infected with
delipidated MTB produce less amount of IL-1β,I L - 6 ,T N F -
alpha, and IL-12 but higher amount of IL-10. MCP-1 and
MIP-1 alpha production is also delayed after delipidation.
Viability of MTB can be restored after addition of pure TDM
[56]. Role of TDM in diﬀerent forms of TB is described in
Table 2.
3.6. Cachexia. Cachexia is caused by accumulation of TDM
in body in which body weight is reduced even on consuming
a proper diet by the animal. Cachectin (TNF) mediates
this condition [5]. In this condition, animals lost ability to
produce granulomas and die of hemorrhagic pneumonia
[57, 58].
4. Conclusion
Mycobacterial lipids have a major role in pathogenicity of
MTB.ThispaperpresentsevidencethatLAMinhibitsphago-
some maturation and TDM inhibits fusion between phos-
pholipid vesicles (phagosomes and lysosomes). Therefore,
it is responsible for the long time survival of MTB in host
body. Because of the presence of these unique characteristics
features, MTB is highly pathogenic. As we all know that
these are not the only factors which provide virulence to
MTB. MTB has a plethora of defense mechanisms against
host immune system and virulence so targeting a single drug
target cannot be a good strategy against MTB infection.
Drug resistance is causing another problem in the way of
eﬀective treatment of TB, so we should always look for newer
drug targets and we can take advantage of the virulence
mechanism of LAM and cord factor in the development of
new drugs. Further research and investigations may lead to
a better understanding for tuberculosis and be helpful in
controling it eﬀectively.
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